BCMA-Targeted Bispecifics and CAR-T in Frontline Multiple Myeloma

At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Rachid Baz, MD, Moffitt Cancer Center, Tampa, Florida, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr Baz highlights early but promising frontline data showing high MRD conversion and unprecedented responses with BCMA-directed therapies, while noting quadruplet regimens remain the standard and earlier integration of these approaches is on the horizon.

Transcript: 

My name is Rashid Baz, I'm a senior member in the department of malignant hematology at Moffitt Cancer Center. I'm here at the LL&M Winter Symposium in Amelia Island.

I presented on the emerging role of BCMA bispecifics and CAR T in the management of transplant-ineligible patients with newly diagnosed multiple myeloma. A key takeaway is that the data are still not mature; however, there are very interesting findings presented at ASH in December evaluating the incorporation of BCMA bispecifics and CAR T into the earlier treatment of newly diagnosed multiple myeloma. For instance, the ImmunoPLANT study showed a 100% MRD conversion rate in patients who received triplet or quadruplet induction. The ALLELE study also demonstrated that the combination of teclistamab and daratumumab resulted in unprecedented response rates and MRD negativity in this population, even without a backbone of IMiDs or proteasome inhibitors. 

The data are early, I think the standard is still a quadruplet regimen for patients who can tolerate it, such as a DRd-V or Isa-RVd backbone. However, we are getting closer to incorporating these newer therapies into the frontline setting.

Source: 

Baz R. The future of frontline treatment for transplant-ineligible patients: Bispecifics vs CAR T. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30 - February 1, 2026. Amelia Island, Florida.